| P/E (FY) | — | Sales (TTM) | $19.1M |
| Earnings (TTM) | -$109.0M | ROE | −33.63% |
| Net Margin | −430.25% | ROIC | −32.50% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
LENZ Therapeutics is a commercial pharmaceutical company focused on developing and commercializing therapies to improve vision in the United States. Its product candidates, VIZZ and LNZ101, are intended for the treatment of presbyopia in adults. Formerly known as Presbyopia Therapies, the company is headquartered in Solana Beach, California.
| Market Cap | $184.4M | Trading Days | 585 |
| 52W High | 50.40 |
| 52W Low | 4.68 |
| % Off High | −88.33% |
| YTD | −63.25% | 1Y | −81.34% |
| Since incept. (ann.) | −35.04% |
Reportable 100%
| Ann. Volatility (1Y) | 81.95% | Ann. Volatility (3Y) | 77.05% |
| Sharpe (1Y) | −1.65 | Sharpe (3Y) | −0.18 |
| Max Drawdown (1Y) | −90.05% | Max Drawdown (3Y) | −90.05% |
| Beta (3Y, vs SPY) | 1.56 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRIS | CURIS INC | $182.8M | — |
| BCDA | BioCardia, Inc. | $186.1M | — |
| VYGR | Voyager Therapeutics, Inc. | $186.7M | — |
| ACOG | Alpha Cognition Inc. | $186.8M | — |
| DTIL | PRECISION BIOSCIENCES INC | $187.1M | — |
| IVVD | Invivyd, Inc. | $179.7M | — |
| PLX | Protalix BioTherapeutics, Inc. | $193.4M | — |
| ALGS | Aligos Therapeutics, Inc. | $173.8M | — |
| BCAB | BioAtla, Inc. | $200.0M | — |
| ALEC | Alector, Inc. | $167.6M | — |
| TNYA | Tenaya Therapeutics, Inc. | $167.0M |
| CRBU | Caribou Biosciences, Inc. | $157.7M | — |
